Full history for every metric is available with a Kvantra account
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 627 | 1,210 | 1,336 | 1,347 | 1,343 | 1,290 | 1,309 | 1,346 |
| Operating profit | $m | 25.9 | 11.8 | ||||||
| Net profit | $m | -61 | -109 | -377 | -281 | -215 | -235 | - | 5 |
| EPS reported | $ | -0.93 | - | ||||||
| Operating cashflow per share | $ | 0.55 | 0.53 | ||||||
| Capex per share | $ | 0.25 | 0.25 | ||||||
| FCF per share | $ | 0.30 | 0.29 | ||||||
| Free cash flow | $m | 75.8 | 76.1 | ||||||
| Net debt | $m | 453 | 505 | ||||||
| Book value equity | $m | 755 | 866 | ||||||
| Book value per share | $ | 2.97 | 3.20 | ||||||
| Number of shares | m | 254.03 | 270.7 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.51 | 2.19 | ||||||
| P/S LTM | x | 1.47 | 1.45 | ||||||
| P/FCF LTM | x | 24.97 | 24.87 | ||||||
| EV/EBITDA LTM | x | 16.65 | 10.79 | ||||||
| EV/Sales LTM | x | 2.19 | 1.83 | ||||||
| Earnings Yield LTM | % | -12.42% | -1.71% | ||||||
| FCF Yield | % | 4.01% | 4.02% | ||||||
| Quality | |||||||||
| ROE | % | -31.14% | -4.47% | ||||||
| ROIC | % | 0.99% | 0.10% | ||||||
| Operating margin | % | 2.01% | 0.91% | ||||||
| Gross margin | % | 38.61% | 43.99% | ||||||
| FCF/Sales | % | 5.87% | 5.78% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -3.91% | +1.75% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | +17.66% | +53.65% | ||||||
| Operating Profit Growth | % | +28.21% | +7.12% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | 0.00% | 0.00% | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.07 | 0.08 | ||||||
| Net Debt/EBITDA | x | 3.86 | 5.23 | ||||||
| EBIT/Net interest | x | 0.25 | 0.12 | ||||||
| Net debt/market cap | % | 23.96% | 26.66% | ||||||
| Net debt/Equity | x | 0.60 | 0.58 | ||||||
| Gross debt/equity | x | 1.37 | 1.05 | ||||||
ETFs that hold Curaleaf Holdings
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| AdvisorShares Pure US Cannabis ETF | MSOS | 3 | 15.86% |
| Amplify Seymour Cannabis ETF | CNBS | 4 | 14.91% |
Funds with Curaleaf Holdings among their ten largest holdings, largest fund first.
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Curaleaf Holdings, Inc. operates as a prominent cannabis company primarily within the United States, managing its business through both domestic and international operating segments. The company's core activities involve the cultivation, production, and distribution of a diverse range of cannabis products, available through both its retail locations and wholesale channels. Its extensive product catalog includes various cannabis forms such as flowers (e.g., pre-rolls, dry-herb vaporizer cartridges), concentrates for vaping (like pre-filled cartridges and disposable pens), concentrates for dabbing (including distillate droppers), edibles, mints, topical balms, lotions, tinctures, lozenges, and capsules. Additionally, Curaleaf provides hemp-derived CBD and cannabigerol products. Established in 2010, the company is headquartered in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Curaleaf Holdings, Inc. (CURA.TO)
| Fund | Ticker | Position# | Weight |
|---|---|---|---|
| AdvisorShares Pure US Cannabis ETF | MSOS | 3 | 15.86% |
| Amplify Seymour Cannabis ETF | CNBS | 4 | 14.91% |
Funds with Curaleaf Holdings among their ten largest holdings, largest fund first.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Curaleaf Holdings, Inc. operates as a prominent cannabis company primarily within the United States, managing its business through both domestic and international operating segments. The company's core activities involve the cultivation, production, and distribution of a diverse range of cannabis products, available through both its retail locations and wholesale channels. Its extensive product catalog includes various cannabis forms such as flowers (e.g., pre-rolls, dry-herb vaporizer cartridges), concentrates for vaping (like pre-filled cartridges and disposable pens), concentrates for dabbing (including distillate droppers), edibles, mints, topical balms, lotions, tinctures, lozenges, and capsules. Additionally, Curaleaf provides hemp-derived CBD and cannabigerol products. Established in 2010, the company is headquartered in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free